|Awarded On||February 21, 2018|
|Title||Dissecting the interplay between BAP1 and PBRM1 in renal cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||James Brugarolas|
|Cancer Sites||Kidney and Renal Pelvis|
Our lab discovered that the gene BAP1 is inactivated in 15% of kidney tumors. Another gene, PBRM1, is inactivated in roughly 50% of kidney tumors. We found that tumors with BAP1 mutations tend not to have mutations in PBRM1. Interestingly, we discovered that tumors with PBRM1 mutations exhibit low grade features and are associated with better prognosis, whereas BAP1-mutant tumors are associated with aggressive features (high tumor grade) and a worse prognosis. Prognosis, however, is the worst in tumors that have mutations in both genes. These findings establish the foundation for a precise classification of kidney cancer that is based on cancer genes (rather than on how the cancer appears un...